J Dig Dis. 2014 Feb;15(2):51-3. doi: 10.1111/1751-2980.12111.
Orthotopic liver transplantation is currently the best treatment option for selected patients with hepatocellular carcinoma (HCC). From 1980 to 2011, 8874 patients with HCC in China underwent liver transplantation. The organ donation classification criteria of China (China criteria), which are established by the Government of China, are divided into three parts: China criteria I, donation after brain death; China criteria II, donation after cardiac death and China criteria III, donation after dual brain-cardiac death. Data from the China Liver Transplant Registry(CLTR) System shows that patients within the Milan criteria have higher survival rates than those who are beyond these criteria. Based on CLTR data, altogether 416 patients received living-donor liver transplantation(LDLT) in China. Their 1-year and 3-year survival rates were significantly higher than those of the non-LDLT recipients. The most common early stage(<30 days after liver transplantation) complications include pleural effusion, diabetes, peritoneal effusion or abscess, postoperative infection, hypertension and intraperitoneal hemorrhage; while the most common late stage (≥ 30 days after liver transplantation) complications were diabetes, hypertension, biliary complications,postoperative infection, tacrolimus toxicity and chronic graft rejection. The incidence of vascular complication, which is the main reason for acute graft failure and re-transplantation, was 2.4%. Liver transplantation is an effective treatment for patients with HCC in China.
原位肝移植是目前治疗肝癌（HCC）的最佳选择之一。从 1980 年到 2011 年，中国有 8874 例 HCC 患者接受了肝移植。中国政府制定的器官捐献分类标准（中国标准）分为三部分：中国标准 I，脑死亡后捐献；中国标准 II，心死亡后捐献和中国标准 III，脑心双死亡后捐献。中国肝移植注册（CLTR）系统的数据显示，米兰标准内的患者比超出这些标准的患者具有更高的生存率。基于 CLTR 数据，中国共有 416 例患者接受了活体供肝肝移植（LDLT）。他们的 1 年和 3 年生存率明显高于非 LDLT 受者。最常见的早期（肝移植后 30 天内）并发症包括胸腔积液、糖尿病、腹腔积液或脓肿、术后感染、高血压和腹腔内出血；而最常见的晚期（肝移植后≥30 天）并发症为糖尿病、高血压、胆道并发症、术后感染、他克莫司毒性和慢性移植物排斥反应。血管并发症的发生率为 2.4%，是急性移植物衰竭和再次移植的主要原因。肝移植是中国 HCC 患者的有效治疗方法。
